Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | MTOR | P42345 | 1/20 | 0.69 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.69 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.69 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.69 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NT5E | P21589 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | ST6GAL1 | P15907 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3608348 | 1.00 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL11617377 | 1.00 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL10177274 | 1.00 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL79966 | 1.00 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL18151989 | 1.00 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL4735554 | 1.00 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL28151155 | 0.96 | LMNA (0.67) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL2537576 | 0.92 | LMNA (0.64) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL11327207 | 0.92 | LMNA (0.64) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL39903 | 0.92 | P2RY2 (0.58) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4679087-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | claimed |
| WO-2024190663-A1 | BIOMARKER AND USE THEREOF | 株式会社明治 | 2024-09-19 | — | — | WO | claimed |
| JP-59031798-A | — | — | None | — | — | JP | disclosed |
| JP-59031798-A | — | — | None | — | — | JP | disclosed |
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4679087-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024190663-A1 | BIOMARKER AND USE THEREOF | 株式会社明治 | 2024-09-19 | — | — | WO | disclosed |
| US-20190142805-A1 | Novel Compounds and Compositions and Methods of Use | ARDEA BIOSCIENCES INC. | 2019-05-16 | — | — | US | disclosed |
| EP-3434773-A2 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2019-01-30 | — | — | EP | disclosed |
| US-10183012-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-10144928-B2 | Double stranded oligonucleotide compounds comprising positional modifications | QUARK PHARMACEUTICALS, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-4839290-A | ANTITUMOR IMMUNOCYTES | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1989-06-13 | — | — | US | disclosed |
| WO-1988004300-A1 | RNA RIBOZYME POLYMERASES, DEPHOSPHORYLASES, RESTRICTION ENDORIBONUCLEASES AND METHODS | UNIVERSITY PATENTS, INC. (US) | 1988-06-16 | — | — | WO | disclosed |
| US-4745054-A | ENZYME LABELS | LONDON BIOTECHNOLOGY LIMITED (GB) | 1988-05-17 | — | — | US | disclosed |
| US-4652554-A | ANTILEUKEMIA AGENT | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 1987-03-24 | — | — | US | disclosed |
| EP-0156641-A2 | Enzymic method of detecting analytes and novel substrates therefor | London Biotechnology Limited (GB) | 1985-10-02 | — | — | EP | disclosed |
| EP-0147689-A2 | A method of inducing antitumor immunocytes, and a process for producing antitumor immunocytes and antitumor immunocytes produced by the process | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1985-07-10 | — | — | EP | disclosed |
| JP-S5931798-A | SYNTHETIC SUBSTRATE CYTIDINE 3'-PHOSPHATE DERIVATIVE AND DETERMINATION OF RIBONUCLEASE ACTIVITY USING THE SAME | AOYANAGI SHOHEI | 1984-02-20 | — | — | JP | disclosed |
| JP-S5931798-A | SYNTHETIC SUBSTRATE CYTIDINE 3'-PHOSPHATE DERIVATIVE AND DETERMINATION OF RIBONUCLEASE ACTIVITY USING THE SAME | AOYANAGI SHOHEI | 1984-02-20 | — | — | JP | disclosed |
| US-4086417-A | ANTILEUKEMIA | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JA) | 1978-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183012-B2 | Compounds and compositions and methods of use | XDH, PON1, OAT | LMNA 258/4885THRB 3250/4885MTOR 3733/4885 |
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ITGB6, ITGA6, ITGA2B | LMNA 443/4885THRB 181/4885MTOR 4845/4885 |
| US-20190142805-A1 | Novel Compounds and Compositions and Methods of Use | XDH, PON1, GLS | LMNA 503/4885THRB 3306/4885MTOR 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.